BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) announced on November 5, 2026, that it has appointed Henry Chow, CPA, CA, as a director, effective the same date, while long-serving board member Ralph Anthony Pullen has stepped down and will remain with the company as an advisor. The governance change comes as BetterLife continues to advance its investigational compound BETR-001 for chronic cluster headache and chronic migraine. Investors may be watching how Chow's deep public-company audit and financial reporting expertise shapes the company's governance posture.

Key Points

  • BetterLife Pharma Inc. (CSE: BETR) announced a board-level governance change effective November 4–5, 2026.
  • Henry Chow, CPA, CA, has been appointed as a director, replacing outgoing board member Tony Pullen, who transitions to an advisory role.
  • Chow brings more than 25 years of public-company audit experience and is founding partner of Saturna Group Chartered Professional Accountants LLP; Pullen is founder of Lumira Capital.
  • Chow will stand for election at the company's annual general and special meeting of shareholders on December 9, 2026.

Henry Chow's Accounting and Public-Company Governance Credentials

Henry Chow is the founding partner of Saturna Group Chartered Professional Accountants LLP, a Vancouver-based firm he established in 2008 that is registered with the Canadian Public Accountability Board and serves approximately 70 public company audit clients. Chow holds more than 25 years of public-company audit experience, covering financial reporting under U.S. GAAP and internal controls under SOX 404. He began his career articling at KPMG LLP in 2000, later became a manager at Manning Elliott LLP in 2005, and has previously served as Chief Financial Officer and/or director of three Canadian-listed public companies.

Tony Pullen's Board Tenure and Ongoing Advisory Commitment

Tony Pullen, founder of life sciences venture firm Lumira Capital, resigned from the board effective November 4, 2026, after supporting BetterLife through its strategic transition to a focused neurology developer. The release states that Pullen will remain with the company as an advisor, maintaining continuity of his life sciences investment perspective. Executive Chairman Doug Drysdale noted in the announcement that Chow's audit and reporting expertise would strengthen governance as BetterLife prepares for its next stage of growth. The immediate share price impact was not clear from available public information.

BETR-001 Development Context and Shareholder Meeting Timing

BetterLife's pipeline centres on BETR-001, a non-hallucinogenic derivative of 2-bromo-lysergic acid diethylamide (2-Br-LSD) in development for the preventive treatment of chronic cluster headache and chronic migraine. The company holds a granted U.S. composition-of-matter patent covering the compound, which remains investigational and has not been approved by any regulatory authority. Chow's appointment as director is subject to shareholder ratification at the company's annual general and special meeting scheduled for December 9, 2026, the announcement confirms.